Navigation Links
Update on the SEAS Study
Date:7/21/2008

LONDON, July 21 /PRNewswire/ -- Professor Terje Pedersen (Ulleval University Hospital, Oslo, Norway), lead investigator for the Simvastatin and Ezetimibe in Aortic Stenosis (SEAS) Study, will provide an update on the study on Monday the 21st July.

Also present in London will be Sir Richard Peto (Professor of Medical Statistics and Epidemiology and Co-director of the Clinical Trials Service Unit, University of Oxford) Professor Rory Collins (BHF Professor of Medicine and Epidemiology at the University of Oxford and Co-director of the Clinical Trials Service Unit) and Professor Ingar Holme, PhD, (Professor of Biostatistics, University of Oslo and Ulleval University Hospital, Oslo, Norway), SEAS steering committee statistician.

The London panel will be joined by Professor Eugene Braunwald (Professor of Medicine at Harvard Medical School) who will participate via Web link from Boston and Professor Robert M Califf (Professor of Medicine, Head of Duke Clinical Research, Duke University) available via phone link.
You are invited to join us at:

The Hilton London Metropole Hotel,

King Suite (3rd Floor, West Wing),

225 Edgware Road, London W2 1JU

When: 21st July at 5.30pm for a 6pm start, BST

OR

The press conference will be Webcast live, and archived, available at:

http://clients.mediaondemand.net/pedersen/live.asx

http://clients.mediaondemand.net/pedersen/archive.asx Additionally the press conference can be accessed via satellite and full coordinates for USA and Europe will be issued by 1pm BST.

There will be a Q&A session after the press announcement. The Q&A session is only available for members of the media.


'/>"/>
SOURCE ;
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. FDA Updates Label for AVANDIA(R) to Include Clinical Findings Demonstrating Sustained Glycemic Control for Up to Five Years
2. Eisai Provides Preliminary Efficacy Update On EORTC Phase III Trial of Dacogen(R) Versus Supportive Care in Patients With Myelodysplastic Syndromes
3. IDM Pharma Provides Update on Mifamurtide (L-MTP-PE) Regulatory Status Following June Meeting of European Committee for Medicinal Products for Human Use (CHMP)
4. SuperGen Comments on Preliminary Efficacy Update on EORTC Phase 3 Trial of Dacogen(R) Versus Supportive Care in Patients With Myelodysplastic Syndromes
5. ELADUR(TM) Development Update: DURECT Receives Orphan Drug Designation for Bupivacaine for Post-Herpetic Neuralgia
6. Genta Updates Progress of its Phase 3 Trial of Genasense(R) in Patients with Advanced Melanoma
7. GSK Update on FDA Review of Promacta(R) (Eltrombopag)
8. XTENT Announces European Regulatory Update
9. Sangamo BioSciences Provides Update on Diabetic Neuropathy Clinical Programs
10. Sunesis Pharmaceuticals Presents Updated Clinical Data From Ongoing Phase 2 Trial of Voreloxin (Formerly SNS-595) in Ovarian Cancer Patients at the 44th ASCO Annual Meeting
11. Genmab Announces Updates on Phase III Cancer Studies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/2/2017)... , Oct. 2, 2017  AllianceRx Walgreens Prime, ... formed by Walgreens and pharmacy benefit manager Prime Therapeutics ... new brand, which included the unveiling of new signage ... , as well as at a few other company-owned ... new brand to patients, some of whom will begin ...
(Date:9/28/2017)... , Sept. 28, 2017 Hill-Rom Holdings, Inc. ... earnings conference call and webcast on Friday, November 3, ... (EDT) and ending at approximately 8:30 a.m. (CDT) / ... the company,s 2017 financial performance and guidance for 2018, ... initiatives to enhance operational performance, and long-range financial outlook ...
(Date:9/27/2017)... and NEW YORK , Sept. 27, 2017 /PRNewswire/ ... health and big data solutions, today announced that its MyDario product is ... your local TV listings for when The Dr. Oz Show airs in ... The nine-time ... month. ...
Breaking Medicine Technology:
(Date:10/12/2017)... ... October 12, 2017 , ... CitiDent and San Francisco ... using cutting-edge Oventus O2Vent technology. As many as 18 million Americans are estimated ... in breathing. Oral appliances can offer significant relief to about 75 percent of ...
(Date:10/12/2017)... ... October 12, 2017 , ... The ... demand of today’s consumer and regulatory authorities worldwide. From Children’s to Adults 50+, ... to meet the highest standard. , These products are also: Gluten Free, ...
(Date:10/12/2017)... ... , ... The American College of Medical Informatics (ACMI) will present the 2017 ... Session of AMIA’s Annual Symposium in Washington, D.C. AMIA’s Annual Symposium is ... pioneer in the field of medical informatics, this prestigious award is presented to an ...
(Date:10/12/2017)... ... October 12, 2017 , ... Information about the ... to develop to enable prevention of a major side effect of chemotherapy in ... in pediatric patients. For cisplatin, hearing loss is FDA listed on-label as a ...
(Date:10/12/2017)... ... October 12, 2017 , ... HMP , a ... of a 2017 Folio Magazine Eddie Digital Award for ‘Best B-to-B Healthcare Website.’ Winners ... October 11, 2017. , The annual award competition recognizes editorial and design excellence across ...
Breaking Medicine News(10 mins):